List of Brisdelle drug patents
Brisdelle is owned by Sebela Ireland Ltd.
Brisdelle contains Paroxetine Mesylate.
Brisdelle has a total of 4 drug patents out of which 0 drug patents have expired.
Brisdelle was authorised for market use on 28 June, 2013.
Brisdelle is available in capsule;oral dosage forms.
Brisdelle can be used as treatment of moderate to severe vasomotor symptoms associated with menopause.
The generics of Brisdelle are possible to be released after 06 April, 2029.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7598271 | SEBELA IRELAND LTD | Crystalline paroxetine methane sulfonate |
May, 2025
(2 years from now) | |
| US8946251 | SEBELA IRELAND LTD | Method of treating thermoregulatory dysfunction with paroxetine |
Aug, 2026
(3 years from now) | |
| US8658663 | SEBELA IRELAND LTD | Method of treating thermoregulatory disfunction with paroxetine |
Apr, 2029
(6 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9393237 | SEBELA IRELAND LTD | Method of treating thermoregulatory dysfunction with paroxetine |
Aug, 2026
(3 years from now) | |
Drugs and Companies using PAROXETINE MESYLATE ingredient
Market Authorisation Date: 28 June, 2013
Treatment: Treatment of moderate to severe vasomotor symptoms associated with menopause
Dosage: CAPSULE;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic